The present disclosure is directed to a cleavable agent for enhanced magnetic resonance generally corresponding to the formula Y-L-R, wherein Y represents a catalyst-binding moiety having at least one isotopically labeled heteroatom, L represents a cleavable bond, and R represents a hyperpolarized payload having at least one isotopically labeled carbon. Also disclosed herein is a method of cleaving the cleavable agent for enhanced magnetic resonance.

This disclosure relates to hyperpolarized probes for use in magnetic resonance studies of biological systems.

Apparatuses and methods for removing caps, such as NMR rotor caps. The apparatuses and methods may permit caps to be removed in a manner that minimizes damage to equipment and instruments. Microwave waveguides that may include an elongated waveguide, a spline horn, and a slotted waveguide. Analytical instruments that include the waveguides.

Apparatuses and methods for removing caps, such as NMR rotor caps. The apparatuses and methods may permit caps to be removed in a manner that minimizes damage to equipment and instruments. Microwave waveguides that may include an elongated waveguide, a spline horn, and a slotted waveguide. Analytical instruments that include the waveguides.

This polarization-transfer apparatus, which induces hyperpolarization with respect to a precursor containing .sup.13C nuclei or .sup.15N nuclei, has a microfluidic device in which the precursor is guided in a magnetic shield such that the strength of the magnetic field acting on the precursor monotonically decreases from approximately 1 μT to zero magnetic field, and then the precursor is guided in the magnetic shield such that the strength of the magnetic field acting on the precursor monotonically increases from zero magnetic field to approximately 1 μT.

There is described a method for preparation of an imaging medium via transfer from a hyperpolarised singlet state that is not parahydrogen, said method comprising the steps of: (i) preparing a system containing: parahydrogen; a magnetisation transfer complex, with a molecular symmetry that allows the creation of a singlet state between spin pairs within it, said complex including a reversibly bound small molecule transference substrate; applying a magnetic field such that hyperpolarisation is transferred into the transfer complex, including the reversibly bound small molecule transference substrate; (ii) introducing a recipient complex capable of binding the small molecule transference substrate, said recipient complex including a recipient substrate, such that the recipient complex and recipient substrate, including the bound transference substrate, is hyperpolarised.

A method and a device for detecting substances and their concentrations in a mixture using magnetic resonance, containing one or more markers deposited on a surface of a carrier in contact with the mixture, wherein the marker is a substance that through intermolecular interactions causes a predetermined orientation of molecules for at least one of the mixture components.

This invention relates to disease detection by imaging and treatment of virus infection. Previously, there was no way to use CEST MRI imaging to early detect and map the neurodegenerative diseases, multiple sclerosis disease, concussion, and traumatic brain injury. Also, previously, there was no way to use Computed Tomography (CT) imaging to early detect and map the neurodegenerative diseases. Embodiments of the present invention use a non-invasive CEST MRI imaging method is disclosed for early detection of diseases by using MRI or by using CT. The endogenous (MRI) contrast of the biological tissue can rely on the endogenous protons of the proteins and peptides as a source of the contrast, such as hydroxyl, amine, and amide protons, and thereby provide imaging and mapping for the early detection of the neurodegenerative diseases, multiple sclerosis disease, concussion, traumatic brain injury, and other diseases by using endogenous protons contrast via CEST MRI. Also, the exogenous agents can be used to produce MRI contrast, such as agents contain exchangeable protons and thereby provide imaging and mapping the inflammation in cancer and the expressed proteins in cancer cells for cancer detection. Also, using exogenous CT contrast agents for detection of amyloid beta, tau protein, alpha-synuclein protein, and aggregation proteins in neurodegenerative diseases and inflammation in many diseases such as neurodegenerative diseases, cancer and other inflammatory diseases Also, this invention relates to novel methods of treatment virus infection and enhance the immune system to produce antibodies against the viruses.

A method for generating magnetic resonance images of a subject includes performing, using a magnetic resonance imaging (MRI) system, a magnetization preparation module to control tissue contrast for a region of interest in the subject. The method further includes after a predetermined period of time, performing, using the MRI system, a three dimensional (3D) unbalanced steady-state free precession (uSSFP) pulse sequence to acquire MR data from the region of interest in the subject. The 3D uSSFP pulse sequence is configured to suppress blood signal in the region of interest. The method further includes generating an image with blood signal suppression based on the acquired MR data.

The present invention relates to compositions and methods using protein reporters as imaging agents in .sup.129Xe NMR and MRI applications. It is described that bla and MBP are genetically-encoded proteins that induce a detectable chemical shift during .sup.129Xe NMR, allowing for use as protein reporters in research and clinical applications.